Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows
Hedge fund bets against Hims & Hers Health hit their highest in at least a year in January, just before…
16,293$
3,12%
Echtzeit-Aktienkurs Hims & Hers Health
Bid:
Ask:
Nachrichten zur Hims & Hers Health Aktie
Options trades to play for a short squeeze in Hims & Hers as the pain piles up
Hims short interest is jumping despite shares getting crushed....…
Hims & Hers Strengthens Integrated Personalized Digital Care Platform
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is redefining healthcare delivery through a consumer-first, digital…
Hims & Hers Strengthens Integrated Personalized Digital Care Platform
HIMS is scaling its personalized, at-home digital care model with new testosterone, menopause and Labs launches as subscribers near 2.5…
Hims & Hers Pulls Wegovy Pill Dupe After FDA Threats — Novo Nordisk Files Patent Lawsuit Anyway
Hims & Hers introduced a $49 per month compounded semaglutide pill in early February— then pulled it from the market…
Hims & Hers Halts Compounded Semaglutide Pill Offering After FDAs Crackdown Warning
Hims & Hers Health Inc. (NYSE:HIMS) has decided to cease offering its compounded semaglutide pill. Hims & Hers Explains Its…
Legal pressures mount for Hims & Hers over GLP-1 sales
Presented by the Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Legal pressures mount for Hims &…
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?
Hims & Hers expands into new specialties and proactive testing while revenue and subscribers grow. However, regulatory, legal and margin…
Novo Nordisk-Aktie im Aufwind: Patentklage setzt Hims & Hers weiter unter Druck
• Novo Nordisk reicht Klage wegen Verletzung des US-Patents 8.129.343 ein• Hims & Hers stoppt die Pläne nach regulatorischem Druck…
FDA Blocks Hims & Hers $49 Compounded Wegovy Pill: What to Know
Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA…
Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’
Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting…
As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?
Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further…
Hims & Hers Aktie unter Beschuss! Kursziel drastisch gesenkt, aber...
Vancouver (www.aktiencheck.de) - Hims & Hers-Aktienanalyse von Canaccord Genuity:Canaccord Genuity habe nach der Klageeinreichung von Novo Nordisk das Kursziel für…
Hims & Hers says Novo Nordisk lawsuit ‘blatant attack’ on millions of Americans
Hims & Hers (HIMS) said in a post on X, formerly Twitter: “Novo Nordisk’s (NVO) lawsuit is a blatant attack…
Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, birds insects,…
Novo Nordisk commences legal action against Hims & Hers
Danish pharma major Novo Nordisk today announced that it has now filed a previously threatened a lawsuit against telehealth…
Wegovy maker Novo Nordisk sues rival over knock-off weight-loss drugs
Novo Nordisk says Hims & Hers drugs breach its patent; Hims & Hers calls the lawsuit a "blatant attack".…
Hims & Hers falls after Novo Nordisk sues co for patent infringement
** Shares of telehealth company Hims & Hers Health NYSE:HIMS fall 3% to $18.74 premarket** Danish drugmaker Novo Nordisk…
Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
Novo Nordisks U.S. patent lawsuit against Hims & Hers , filed on Monday, marks a new front in the Danish…
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit
Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and…